NYSEAMERICAN:SENS - Senseonics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.64 -0.08 (-2.94 %)
(As of 03/21/2019 04:00 PM ET)
Previous Close$2.72
Today's Range$2.62 - $2.82
52-Week Range$2.15 - $5.29
Volume1.80 million shs
Average Volume1.82 million shs
Market Capitalization$467.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive SENS News and Ratings via Email

Sign-up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SENS
Previous SymbolNASDAQ:SENS
CUSIPN/A
CIKN/A
Phone+1-301-5157260

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$467.17 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions

What is Senseonics' stock symbol?

Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."

How were Senseonics' earnings last quarter?

Senseonics Holdings Inc (NYSEAMERICAN:SENS) posted its earnings results on Tuesday, March, 12th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.11. The business earned $7.20 million during the quarter, compared to analysts' expectations of $7.89 million. View Senseonics' Earnings History.

When is Senseonics' next earnings date?

Senseonics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Senseonics.

What guidance has Senseonics issued on next quarter's earnings?

Senseonics issued an update on its FY 2019 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25-30 million, compared to the consensus revenue estimate of $30.14 million.

What price target have analysts set for SENS?

8 brokerages have issued 12 month price objectives for Senseonics' stock. Their predictions range from $5.00 to $7.00. On average, they expect Senseonics' share price to reach $6.00 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Senseonics.

What is the consensus analysts' recommendation for Senseonics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Senseonics.

What are Wall Street analysts saying about Senseonics stock?

Here are some recent quotes from research analysts about Senseonics stock:
  • 1. According to Zacks Investment Research, "Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. " (2/6/2019)
  • 2. BTIG Research analysts commented, "Senseonics’ reported Q2 sales relatively in line with our estimates and Street expectations. That put the focus squarely on observations from the first days of US launch. Early feedback points to doctors quickly becoming comfortable with the procedure and patients enjoying a long-lasting sensor. Additionally, revenue guidance for 2018 was increased by $1M because of additional confidence in both Europe and the US. We see this as a positive following FDA approval. In our view, the only factor hindering US patient and clinician appetite for Eversense is the timing of payor coverage, which we see as an issue of when, not if. We continue to model 2018 sales slightly above the guidance range. Although SENS shares have been weak since the company’s recent financing, we think shares may trade flat to slightly up Thursday with mgmt raising expectations a bit." (8/9/2018)

Has Senseonics been receiving favorable news coverage?

Media coverage about SENS stock has been trending neutral recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Senseonics earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the next few days.

Are investors shorting Senseonics?

Senseonics saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 28,731,638 shares, an increase of 10.4% from the February 15th total of 26,016,880 shares. Based on an average trading volume of 2,934,237 shares, the short-interest ratio is currently 9.8 days. Currently, 31.7% of the shares of the stock are short sold. View Senseonics' Current Options Chain.

Who are some of Senseonics' key competitors?

What other stocks do shareholders of Senseonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Senseonics investors own include CytoDyn (CYDY), Tandem Diabetes Care (TNDM), TransEnterix (TRXC), VirnetX (VHC), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), TherapeuticsMD (TXMD) and CymaBay Therapeutics (CBAY).

Who are Senseonics' key executives?

Senseonics' management team includes the folowing people:
  • Dr. Timothy T. Goodnow, Pres, CEO & Director (Age 57)
  • Dr. Mukul Jain, Chief Operating Officer (Age 46)
  • Mr. Jon D. Isaacson, Chief Financial Officer
  • Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 54)
  • Dr. Abhi Chavan Ph.D., VP of Engineering and R&D

Who are Senseonics' major shareholders?

Senseonics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.47%), Massachusetts Financial Services Co. MA (2.09%), City Financial Investment Co Ltd (0.82%), Northern Trust Corp (0.57%), Raymond James Financial Services Advisors Inc. (0.56%) and Raymond James & Associates (0.48%). Company insiders that own Senseonics stock include Douglas A Roeder, Enterprise Associates 10 L New, Mukul Jain and Peter J Barris. View Institutional Ownership Trends for Senseonics.

Which institutional investors are selling Senseonics stock?

SENS stock was sold by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., Millennium Management LLC, Granite Point Capital Management L.P., MetLife Investment Advisors LLC and Mirae Asset Global Investments Co. Ltd.. Company insiders that have sold Senseonics company stock in the last year include Douglas A Roeder and Mukul Jain. View Insider Buying and Selling for Senseonics.

Which institutional investors are buying Senseonics stock?

SENS stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Prescott Group Capital Management L.L.C., City Financial Investment Co Ltd, BlackRock Inc., Citigroup Inc., Wesbanco Bank Inc., Bank of New York Mellon Corp and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Senseonics.

How do I buy shares of Senseonics?

Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Senseonics' stock price today?

One share of SENS stock can currently be purchased for approximately $2.64.

How big of a company is Senseonics?

Senseonics has a market capitalization of $467.17 million.

What is Senseonics' official website?

The official website for Senseonics is http://www.senseonics.com/.

How can I contact Senseonics?

Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.


MarketBeat Community Rating for Senseonics (NYSEAMERICAN SENS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel